07:44 AM EDT, 10/08/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday that its Keytruda treatment met the primary endpoint of event-free survival in the late-stage Keynote-689 trial for patients with stage III or IVA resected, locally advanced head and neck squamous cell carcinoma.

Merck ( MRK ) said the trial evaluated Keytruda as perioperative treatment before surgery and in combination with standard-of-care radiotherapy as adjuvant therapy, and that the safety profile of Keytruda was consistent with previous studies.

Price: 108.49, Change: -0.10, Percent Change: -0.09